Skip to content

Cohort of Children with Overweight and Obesity in Hunan Province

Multicenter Prospective Cohort Study on Overweight and Obesity in Children in Hunan Province

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118251
Enrollment
Unknown
Registered
2026-02-03
Start date
2026-02-16
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary overweight or obesity

Interventions

Group of Healthy Children with Normal Weight:none
Group of Children with Overweight and Obesity:None

Sponsors

Xiangya Hospital Central South University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1.Legal guardians provide consent and sign the informed consent form, and the child (age >=6 years) concurrently provides assent using a child-friendly version of the form; 2.Age between 6 and 18 years (inclusive); 3.Diagnosed with primary overweight or obesity in a specialist clinic, typically corresponding to a BMI >=85th percentile for age and sex, with or without related complications; 4. Healthy group: normal weight (usually corresponds to a BMI between the 5th and 85th percentiles for age and sex)

Exclusion criteria

Exclusion criteria: 1.Presence of secondary causes of obesity, such as endocrine disorders, drug-induced obesity (e.g., due to glucocorticoids, antidepressants like mirtazapine/paroxetine, or antipsychotics like clozapine/olanzapine), syndromic obesity, or monogenic obesity; 2.Diagnosis of Type 1 Diabetes; 3.Coexisting malignancies or severe cardiac, pulmonary, renal, or hepatic dysfunction not attributable to obesity; 4.History of severe cardiovascular or cerebrovascular events within the past 6 months; 5.History of severe gastrointestinal diseases or gastrointestinal surgery within the past 12 months; 6.Current use of medications (other than approved anti-obesity drugs) that are known to affect body weight or energy balance; 7.Concurrent participation in another clinical trial; Health group: Type 1 or Type 2 diabetes, insulin resistance, hyperlipidemia, primary or secondary hypertension, fatty liver, etc.

Design outcomes

Primary

MeasureTime frame
Weight;Body mass index;

Secondary

MeasureTime frame
Blood sugar;Insulin resistance index;Blood lipid;Rate of weight regain;

Countries

China

Contacts

Public ContactLuo Xianghang

Xiangya Hospital Central South University

xianghangluo@csu.edu.cn+86 731 89752728

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026